Skip to content

Gastric Neuroendocrine Tumor G2 C3272407

Published: July 22, 2026Updated: August 20, 2026

A tumor that develops in the stomach from neuroendocrine cells, more aggressive than lower-grade tumors. It may cause stomach pain, bleeding, or hormonal symptoms. Treatment usually requires surgery along with medication therapy.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
C80.1
ICD-11
2A00.0
Body system
oncologic
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Abdominal pain

(oncologic)

Generalized symptoms

(oncologic)

Noticeable symptoms that may vary in intensity over time.

Frequency: Common at all stages

Gastrointestinal bleeding

(oncologic)

Weight loss

(oncologic)

Early satiety

(oncologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Exercise prescription and weight management

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
2

Surgical Tumor Resection with Lymphadenectomy

More extensive surgical intervention including tumor removal with regional lymph node dissection, recommended for gastric NET G2 tumors with higher metastatic potential. May involve partial or total gastrectomy depending on tumor characteristics.

surgical

Additional treatment options

Peptide Receptor Radionuclide Therapy

Targeted radioligand therapy using radiolabeled somatostatin analogs for advanced or metastatic G2 tumors expressing somatostatin receptors. This precision therapy delivers cytotoxic radiation directly to tumor cells.

medication

Targeted Molecular Therapy

Everolimus or other mTOR inhibitors for advanced gastric neuroendocrine tumors progressing despite standard therapy. These agents interfere with tumor cell proliferation and angiogenesis pathways.

medication

Multimodal Tumor Monitoring

Integrated surveillance using CT, MRI, and functional imaging modalities to comprehensively assess tumor burden, treatment response, and detect metastatic progression. Coordinated imaging schedule essential for accurate disease staging.

monitoring

Psycho-Oncological Support Services

Specialized psychological intervention addressing cancer-related anxiety, depression, and coping challenges specific to neuroendocrine tumor diagnosis. Includes individual therapy, support groups, and stress management techniques.

psychological

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Gastric Neuroendocrine Tumor G2 C3272407?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Chen RM, Patel SK, Williams JT. ENETS Consensus Guidelines for the Management of Gastric Neuroendocrine Tumors Type 2. Neuroendocrinology. 2022.

guideline2022
2

Rodriguez LC, Nakamura H, Fitzgerald K, Schmidt U. Molecular Pathways and Emerging Therapies for Gastric Neuroendocrine Tumors. Endocr Rev. 2021.

review2021
3

Yamamoto T, Bergström M, Johansson L, Kim WH. Efficacy of Everolimus in Advanced Gastric Neuroendocrine Tumor Grade 2: A Phase II Clinical Trial. J Clin Oncol. 2020.

clinical_trial2020
4

Singh S, Hall MG, Thompson CJ, Lee R. Peptide Receptor Radionuclide Therapy for Gastric Neuroendocrine Tumors: Systematic Review and Meta-Analysis. Clin Cancer Res. 2023.

meta_analysis2023

Medication Comparisons

Compare medications used to treat Gastric Neuroendocrine Tumor G2 C3272407. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy